From a clinical standpoint, these subtle biochemical shifts should be interpreted within the broader context of robust reductions in HF events and mortality consistently observed across SGLT2 inhibitor trials [3-7,19,21,29,30,32,35-49]. Here, SLC5A2 is linked to hydrops fetalis.